Navigation Links
Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for pandemic disease threats, announced today a new scientific report featuring its antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as "bird flu." Alferon-LDO is a low-dose experimental oral formulation of the Company's Alferon-N(TM) product, which is already approved by the United States FDA for the treatment of refractory genital warts (HPV).

The report concludes that Alferon-LDO appears to have potential as a preventive agent and/or treatment against avian influenza, reducing the severity of pathology resulting from infection of established animal model non-human primates (macaques) by a highly pathogenic strain of avian flu.

As noted in a 2006 Oxford University Clinical Research Unit study titled "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia," illness caused by the avian influenza A virus stems most directly from the body's own response to infection, an overwhelming reaction sometimes termed a "cytokine storm." In the words of the Oxford University study, "high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment."

To study the effects of Alferon-LDO, researchers administered macaque subjects with the drug via the animals' gum tissues, in a range of three dosing concentrations, with a fourth untreated group serving as a control. Following exposure of the dosed and untreated test subjects to the highly pathogenic HPAI strain A/Vietnam/1194/04, throat and nasal swabs were taken, gross pathology and viral lo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:8/19/2014)... 19, 2014   Lincor Inc. today ... technology to New Jersey -based ... CarePoint Health will deploy Lincor,s PatientLINC technology across ... Hospital and Hoboken University Medical Center. ... software solutions to help hospitals reach new levels ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Talyst Exhibits at the NPPA Summer Conference 2
(Date:8/19/2014)... The National Cannabis Industry Association ... Symposium on Saturday, August 23, from 9:45am to ... Vegas. , Featuring keynotes by U.S. Representative Dina Titus ... the event will also include in-depth discussions on marijuana-infused ... doing federally to advance a legitimate and responsible cannabis ...
(Date:8/19/2014)... Plains, NY (PRWEB) August 19, 2014 ... they were named the winner of the 2014 ... Naturals took home the first place position in ... the marketplace specially-formatted eyeliner, which also includes a ... rich black color, plus lash-boosting technology. ...
(Date:8/19/2014)... 19, 2014 Just back from Glasgow where ... Booklets at the Commonwealth Games (July 23 – August ... kids stay off drugs. And the need for his work ... 850,000 people age16 to 59 consumed Class A drugs within ... abusing New Psychoactive Substances (NPS) drugs considered to be “legal ...
(Date:8/19/2014)... stay and could use this time as an opportunity to ... home. Now a study published in the August 20 ... the proportion of hospitalized smokers who successfully quit smoking after ... interactive voice response technology automated telephone calls to ... left the hospital. , "Most smokers want to ...
(Date:8/19/2014)... Program has selected three geriatric social work ... development and mentorship for projects that will improve ... for all older adults. , The 2014 Hartford/VA ... among veterans, transitions from VA nursing facilities back ... older veterans. The Hartford/VA Geriatric Scholars Program provides ...
Breaking Medicine News(10 mins):Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2
... The Kerlan Jobe Orthopaedic Clinic, a sports medicine clinic in ... million to settle allegations that it received illegal kickbacks from ... , The settlement resolves allegations that HealthSouth paid ... grants, donations to the Kerlan Jobe Foundation, loan forgiveness on ...
... , LOS ANGELES, Dec. 1 A decision issued ... Board (NLRB) has put at risk the guaranteed raises, healthcare ... professionals in Southern California. , "We have worked for years ... allow us to provide the professional care our patients need," ...
... tomography (CT) imaging of changes in tumors from colorectal ... have the potential to predict overall survival, according to ... JAMA . The addition of bevacizumab to ... survival in patients with stage IV colorectal cancer and ...
... , , ... (ASH) will host its annual High School Student Symposium at ... a.m. CST. The symposium, which encourages an interest in hematology, ... with the Society,s 51st Annual Meeting. This year, students will ...
... , MEXICO CITY, Dec. 1 ... will build a world-class center for biomedical and nanomedical ... research and development will be integrated with the National ... in the world. The research complex, scheduled to ...
... , BELLEVUE, Wash., Dec 1 Edifecs, ... Channel Modernization solutions announced an enhanced release of Edifecs ... migrations. XEngine Translator provides out-of-the-box 4010A1-5010 conversion maps, allows ... 4010A1 and 5010 in production, thus addressing most requirements ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3Health News:Mexico City to Build World-Class Hub for Medical Research 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: